Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.42M | $155M | $301M | $381M | $456M | $612M | $844M | $1.14B | $1.79B | $1.86B |
| Revenue growth | — | 2751.6% | 94.7% | 26.5% | 19.7% | 34.3% | 37.8% | 35.7% | 56.2% | 4.3% |
| Operating income | -$267M | -$172M | -$344M | -$706M | -$564M | -$460M | -$536M | -$268M | $218M | -$700M |
| Operating margin | -4920.3% | -111.0% | -114.1% | -185.3% | -123.8% | -75.1% | -63.5% | -23.4% | 12.2% | -37.5% |
| Net income | -$267M | -$50.7M | -$362M | -$715M | -$554M | -$419M | -$703M | -$536M | $235M | -$713M |
| Net margin | -4930.2% | -32.8% | -120.2% | -187.8% | -121.6% | -68.4% | -83.4% | -46.8% | 13.2% | -38.3% |
| EPS (diluted) | -$5.49 | -$0.86 | -$5.46 | -$9.71 | -$7.11 | -$5.15 | -$8.03 | -$5.80 | $2.34 | -$7.13 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$246M | -$232M | -$389M | -$456M | $107M | -$443M | -$325M | -$501M | -$206M | -$205M |
| Capital expenditures | $5.34M | $12.0M | $61.2M | $59.6M | $82.2M | $38.5M | $30.8M | $76.1M | $137M | $102M |
| Free cash flow | -$251M | -$244M | -$450M | -$516M | $25.3M | -$482M | -$356M | -$577M | -$343M | -$307M |
| Share buybacks | — | — | — | — | — | — | — | $0.00 | $0.00 | $25.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $122M | $600M | $371M | $835M | $1.50B | $2.12B | $967M | $428M | $1.10B | $801M |
| Total assets | $424M | $1.31B | $1.64B | $1.82B | $2.98B | $3.15B | $3.13B | $3.26B | $3.96B | $3.35B |
| Total liabilities | $87.4M | $519M | $610M | $1.00B | $2.22B | $2.22B | $2.74B | $2.41B | $2.44B | $2.21B |
| Long-term debt | $17.7M | $431M | $421M | — | — | $564M | $1.54B | $1.24B | $1.14B | $141M |
| Shareholders' equity | $337M | $789M | $1.03B | $818M | $762M | $928M | $385M | $859M | $1.53B | $1.14B |
| Retained earnings | -$1.17B | -$1.22B | -$1.58B | -$2.29B | -$2.85B | -$3.21B | -$3.91B | -$4.45B | -$4.21B | -$4.88B |
| Shares (wtd avg diluted) | 48.7M | 58.8M | 66.3M | 73.6M | 78.0M | 81.3M | 87.6M | 92.4M | 108M | 100M |
Every figure is extracted from Sarepta Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.